Vertex Pharmaceuticals (VRTX) EBIAT (2016 - 2025)
Historic EBIAT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.
- Vertex Pharmaceuticals' EBIAT rose 358.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 86596.5%. This contributed to the annual value of -$535.6 million for FY2024, which is 11479.72% down from last year.
- As of Q3 2025, Vertex Pharmaceuticals' EBIAT stood at $1.1 billion, which was up 358.71% from $1.0 billion recorded in Q2 2025.
- In the past 5 years, Vertex Pharmaceuticals' EBIAT ranged from a high of $1.1 billion in Q1 2024 and a low of -$3.6 billion during Q2 2024
- In the last 5 years, Vertex Pharmaceuticals' EBIAT had a median value of $851.9 million in 2021 and averaged $605.8 million.
- As far as peak fluctuations go, Vertex Pharmaceuticals' EBIAT soared by 110970.15% in 2022, and later tumbled by 49244.29% in 2024.
- Quarter analysis of 5 years shows Vertex Pharmaceuticals' EBIAT stood at $770.1 million in 2021, then grew by 6.34% to $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then grew by 18.61% to $1.1 billion in 2025.
- Its EBIAT was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $646.3 million in Q1 2025.